Actively Recruiting
Evaluation of Lurbinectedin Combined With Durvalumab as First-Line Maintenance Therapy for Extensive-Stage Small-Cell Lung Cancer After Platinum-Based Chemotherapy and Durvalumab Induction
Led by Jazz Pharmaceuticals · Updated on 2026-09-17
50
Participants Needed
5
Research Sites
12 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effectiveness of lurbinectedin combined with durvalumab as a maintenance therapy for participants with extensive-stage small-cell lung cancer ES-SCLC whose disease has not progressed following first-line induction therapy. This study focuses on individuals who have received initial treatment with durvalumab plus platinum and etoposide chemotherapy and have ongoing complete response, partial response, or stable disease after these treatments. Participants will receive lurbinectedin and durvalumab through intravenous infusions as maintenance therapy after completing four cycles of platinum-based chemotherapy and at least three cycles of durvalumab during induction therapy. The study is open-label and single-arm, assessing this combination as a first-line maintenance treatment following the initial chemotherapy and durvalumab regimen. During the study, participants will be monitored regularly for progression-free survival and overall response rates for up to two years. Safety will also be assessed by tracking dose modifications and treatment discontinuations. Blood samples will be collected to measure plasma concentrations of lurbinectedin over the first three months. Participants health status and side effects will be carefully recorded throughout the study period until its completion in 2028.
CONDITIONS
Brief Title
A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC
Research Team
C
Clinical Trial Disclosure & Transparency
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here